SLRN ACELYRIN INC

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates.

A live webcast of the conference call will be available on the Company’s website under . A replay of the webcast will be available on the Company’s website for 90 days.

About ACELYRIN

ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN’s lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease.

For more information about ACELYRIN, visit us at or follow us on and .

Forward Looking Statements

Some statements in this press release are, or may be considered, forward-looking statements, including statements regarding ACELYRIN’s progress, business plans and clinical trials, as well as the potential future benefits of our product candidates. While ACELYRIN, INC. considers any projections to be based on reasonable assumptions, these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated in such forward-looking statements.

ACELYRIN Contacts:

Tyler Marciniak

Vice President of Investor Relations and Corporate Affairs

  



EN
06/11/2024

Underlying

SLRNACELYRIN INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ACELYRIN INC

 PRESS RELEASE
Free
SLRN ACELYRIN INC

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (“Rights Plan”). The ACELYRIN Board and management team continue to engage with stockholde...

March 13, 2025 1 EN
 PRESS RELEASE
Free
SLRN ACELYRIN INC

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Prop...

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, “Alumis a...

March 4, 2025 1 EN
 PRESS RELEASE
Free
SLRN ACELYRIN INC

ACELYRIN Determines Unsolicited Indication of Interest From Concentra ...

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of D...

March 4, 2025 1 EN
 PRESS RELEASE
Free
SLRN ACELYRIN INC

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from C...

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represen...

February 21, 2025 1 EN
 PRESS RELEASE
Free
SLRN ACELYRIN INC

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma ...

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN’s lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approxima...

February 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch